Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism
Flora
; 27(2):324-334, 2022.
Article
in English
| EMBASE | ID: covidwho-2033381
ABSTRACT
Introduction:
Dipeptidyl peptidase-4 (DPP4) has been shown to be a functional receptor for MERS-CoV. An interaction between the viral spike protein and DPP4 is thought to facilitate viral entry. We aimed to find out whether sitagliptin, a member of DPP4 inhibitors, would have beneficial effects in COVID-19 patients. Materials andMethods:
In this single center retrospective study, we evaluated 58 patients of whom 16 were on sitagliptin treatment. Molecular docking studies were performed to identify possible interactions between ACE2 and sitagliptin.Results:
Sitagliptin use shortened the time to clinical recovery about 3.5 and fastened viral clearance more than 5 days. Resolution of all symptoms was achieved on a mean±standard error (SE) of 2.50 ± 0.40 days in sitagliptin (+) group and 5.69 ± 0.61 days in sitagliptin (-) group (Log-rank test, p< 0.001). PCR tests for SARS-CoV-2 resulted negative in mean ± SE of 7.50 ± 0.98 days in sitagliptin (+) and 13.17 ± 1.07 days in sitagliptin (-) group (Log-rank test, p= 0.003). Compared to day 0, CRP, ferritin and D-dimer levels on days three, five, and seven were significantly lower whereas lymphocyte count was higher in sitagliptin (+) group.Conclusion:
Our results suggest that sitagliptin seems to have a potential to be considered for the treatment of COVID-19.
angiotensin converting enzyme 2; D dimer; favipiravir; ferritin; hydroxychloroquine; sitagliptin; adult; article; controlled study; coronavirus disease 2019; disease course; drug repositioning; female; human; major clinical study; male; middle aged; molecular docking; protein blood level; retrospective study; viral clearance
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Prognostic study
Language:
English
Journal:
Flora
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS